Protective effects of pharmacological therapies in animal models of multiple sclerosis: a review of studies 2014–2019

Bridget Martinez1,2, Philip V. Peplow1,***
1 Physical Chemistry and Applied Spectroscopy, Chemistry Division, Los Alamos National Laboratory, Los Alamos, NM, USA
2 Department of Medicine, St. Georges University School of Medicine, True Blue, Grenada
3 Department of Anatomy, University of Otago, Dunedin, New Zealand

Abstract
Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system. The disability caused by inflammatory demyelination clinically dominates the early stages of relapsing-remitting MS and is reversible. Once there is considerable loss of axons, MS patients enter a secondary progressive stage. Disease-modifying drugs currently in use for MS suppress the immune system and reduce relapse rates but are not effective in the progressive stage. Various animal models of MS (mostly mouse and rat) have been established and proved useful in studying the disease process and response to therapy. The experimental autoimmune encephalomyelitis animal studies reviewed here showed that a chronic progressive disease can be induced by immunization with appropriate amounts of myelin oligodendrocyte glycoprotein together with mycobacterium tuberculosis and pertussis toxin in Freund’s adjuvant. The clinical manifestations of autoimmune encephalomyelitis disease were prevented or reduced by treatment with certain pharmacological agents given prior to, at, or after peak disease, and the agents had protective effects as shown by inhibiting demyelination and damage to neurons, axons and oligodendrocytes. In the cuprizone-induced toxicity animal studies, the pharmacological agents tested were able to promote remyelination and increase the number of oligodendrocytes when administered therapeutically or prophylactically. A monoclonal IgM antibody protected axons in the spinal cord and preserved motor function in animals inoculated with Theiler’s murine encephalomyelitis virus. In all these studies the pharmacological agents were administered singly. A combination therapy may be more effective, especially using agents that target neuroinflammation and neurodegeneration, as they may exert synergistic actions.

Key Words: animal models; autoimmune encephalomyelitis disease; cuprizone-induced toxicity; multiple sclerosis; neurodegeneration; neuroinflammation; neuroprotection; pharmacological agents; progressive disease; Theiler’s murine encephalomyelitis virus

Introduction
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS). It is the main cause of non-traumatic neurological disability in young adults in the USA and Europe (Dutta and Trapp, 2011). Several phenotypes of MS have been recognized which include relapsing-remitting (RRMS) and progressive phenotypes (secondary and primary, SPMS and PPMS). Acute relapses are pathologically associated with inflammatory demyelination of the white matter, whereas disease progression is pathologically associated with irreversible damage to neurons. Inflammation may decrease in the late relapsing stage to levels found in age-matched controls; however, age- and disease-related neurodegeneration occurs which affects the damaged brain and spinal cord, causing further disability progression. In this stage of the disease, anti-inflammatory treatments are unlikely to be of benefit but neuroprotective and repair-inducing treatments may be successful (Lassman, 2017). Relapses and new lesions in patients with RRMS have been prevented by disease-modifying treatments that primarily target adaptive immunity, but they have limited efficacy on disability progression (Zhang et al., 2013). In a recent review Kantarci et al. (2014) wrote “No established treatment significantly impacts the neurodegenerative component of progressive disease course in MS. Any effect seen is seemingly related to prevention of ongoing relapses. Different and more effective strategies are needed to prevent lesions long before the progressive phase starts. The future prevention of MS-related disability will probably depend on how effectively we can design treatment protocols to prevent progressive disease course in MS.” A drug that promotes endogenous remyelination and/or decreases axonal degeneration would reduce the rate and degree of disease progression (Moore et al., 2014a). All currently licensed immunomodulatory therapies for MS do not support remyelination directly (Williams, 2015; Strangel et al., 2017).

The use of animal models of MS allows for investigating and furthering an understanding of the pathological changes during the disease course and the testing of new therapies (Hochstrasser et al., 2018; Burrows et al., 2019). These models include animals (commonly rodents) in which experimental autoimmune encephalomyelitis (EAE) has been developed. They have been used to study white matter inflammatory demyelination which inhibits axonal conduction and suppression of inflammation causes recovery. They also allow a study of disease course viz. relapsing or progressive disease. Another model is the cuprizone (CPZ) model in which oligodendrocyte apoptosis leads to innate immune ac-
tivation and finally demyelination. A third model is the Thei-
ler's murine encephalomyelitis virus (TMEV) model and can
be used to study progressive MS. The virus infects glial cells
and macrophages during the chronic disease phase, which
leads to inflammatory demyelination with oligodendrocyte
apoptosis and axonal degeneration.

Neurodegeneration occurs to a variable extent in these
models. In the EAE and TMEV models, tissue damage is
mainly due to activation of the acquired immune system,
whereas in the CPZ model activation of the innate immune
system results in tissue damage. Interestingly, combining the
immunomodulatory peptide, tuftsin, with benztropine, a
remyelination-stimulating drug, alleviated symptoms in an
EAE model and decreased pathological hallmarks in both
EAE and CPZ models of MS. Tuftsin changed the inflamma-
tory CNS environment normally present in the EAE model
into an anti-inflammatory one, and benztropin improved remy-
elination in the CPZ model (Thompson et al., 2018). Other
toxin-induced animal models of MS include use of ethidium
bromide and lysolecithin to cause myelin damage (van der
toxin-induced animal models of MS include use of ethidium
bromide and lysolecithin to cause myelin damage (van der

We have performed a search of articles on the PubMed da-
base for the period January 2014–May 2019 to evaluate the
progress made in the testing of neuroprotective agents in an-
imal models of MS and whether they are able to reduce the
loss of neurons and axons in the chronic phase of the disease
and impede disability progression which had been suggested
as challenges in the review by Kantarci et al. (2014).

Animal Models of Multiple Sclerosis Disease
The most characterized animal models of MS are the EAE
model, the toxin-induced model (CPZ model), and TMEV
infection model (Procaccini et al., 2015).

Experimental autoimmune encephalomyelitis animal
model
This is the most used animal model of MS. EAE is charac-
terized by inflammatory infiltrates of T lymphocytes, B
lymphocytes, macrophages and focal demyelinating plaques
in the CNS. The cytokines and other factors released by the
infiltrating cells cause oligodendrocyte degeneration. EAE
can be induced in various species, including rodents and
primates, either by active immunization using a myelin an-
tigen in adjuvant (active EAE) or by the adoptive transfer of
encephalitogenic T cells (passive EAE).

The commonly used EAE mouse models exhibit motor
dysfunction as ascending paralysis, beginning with a flaccid
or limp tail (Stormnes and Goverman, 2006a; Baxter, 2007).
The paralysis progresses from the hind limbs to the fore
limbs and is sometimes followed by urinary incontinence
and fecal impaction (classical EAE models). In classical EAE,
inflammatory infiltration begins at the lumbar region of the
spinal cord (Juźwik et al., 2018). The standard EAE mouse
model is induced using myelin proteolipid protein (PLP)
peptide (amino acids 139–151), which causes relapse-remit-
tting EAE in SJL mice. In addition, the myelin oligodendro-
cyte glycoprotein (MOG) peptide (amino acids 35–55) caus-
es monophasic EAE in C57BL/6 mice with an incomplete
recovery (Gold et al., 2006). Several studies have demon-
strated real primary progressive or secondary progressive
EAE, in which mice die as a result of disease progression
(Tsunoda et al., 2000). Variations from classical EAE pheno-
type include ataxia or head rolling rather than limb paral-
ysis, and are referred to as atypical EAE (Sobel, 2000). The
observed clinical signs in atypical EAE models are associated
with increased inflammation in the brain compared to clas-
sical EAE models (Takeuchi et al., 2013).

In the active EAE model, mice are immunized by subcuta-
naneous injection (s.c.) of the myelin antigen with Freund's
adjuvant and Mycobacterium tuberculosis. The incidence of
EAE induction is increased by intravenous or intraperito-
eal (i.p.) injection of pertussis toxin. The signs of motor
dysfunction depend on the type of EAE model, and paralysis
usually begins 9 to 14 days after sensitization (Stormnes and
Goverman, 2006a). Passive EAE is induced in naïve mice
by the adoptive transfer of T cells isolated from active EAE
mice that have been sensitized with myelin antigens. Visible
signs of EAE usually appear 10 to 15 days after induction
(Stormnes and Goverman, 2006b). The severity of EAE is
usually evaluated using an EAE scoring system, with mice
being examined daily after the day of sensitization to accu-
rately detect the time of disease onset and to monitor the
progression of EAE. In most studies, a 0 to 5 point scale is
used: 0, refers to no clinical signs; 1, paralyzed tail; 2, loss
in coordinated movement, hind limb paralysis; 3, both hind
limbs paralysis; 4, fore limbs paralysis; 5, moribund or death
(Stormnes and Goverman, 2006a). The mice are weighed
daily and scored for EAE signs after sensitization. A decrease
in body weight that usually precedes paralysis is common in
EAE, and lowered body weight remains during the recovery
phase (Encinas et al., 2001). Body weight begins to increase
during the chronic phase of the disease; hence, body weight
loss is an important sign during the acute stage of EAE.

Cuprizone mouse model
Treatment with CPZ, a copper chelator, is the most fre-
quently used of the toxin-induced models of MS. It is used to
study mechanisms of oligodendrocyte turnover, astrogli-
osis and microgliosis (Blakemore and Franklin, 2008). As
opposed to other toxin-induced models, in which the toxin
is introduced into the brain by stereotactic microinjections
and causes focal demyelination, oral administration of CPZ
produces a global insult. Different rodent strains respond
to CPZ treatment in distinctive ways and is best shown in the
C57BL/6 strain. Unlike C57BL/6 mice, BALB/c mice develop a
delayed and incomplete demyelination in specific brain
regions following CPZ treatment (Skripuletz et al., 2008). Rats are resistant to CPZ-induced demyelination and are not a suitable model to study remyelination processes
(Love, 1988). Female mice are more resistant to demyelin-
ation induced by CPZ (Taylor et al., 2009), so typically male
C57BL/6 mice are fed CPZ, which leads mainly to selective
oligodendrocyte death and reproducible demyelination in the
brain (Hibbits et al., 2009; Steelman et al., 2012). Brain
lesions in CPZ-fed mice can be shown by a MRI technique, but no dependable noninvasive method exists to distinguish the rate of remyelination in such mice from that in untreated animals. This necessitates the killing of animals in order to collect the corpus callosum and determine the effects of the toxicant, making it difficult to perform longitudinal studies. Consequently a large number of mice are required to sufficiently statistically power the studies.

CPZ causes demyelination by directly killing oligodendrocytes in the mouse brain. Treatment with CPZ is unlikely to mimic the complex pathology of relapsing-remitting MS and secondary progressive MS in humans (MacArthur and Papa-nikolaou, 2014).

As oligodendrocyte precursors mature, robust myelin repair can be observed in CPZ-fed mice after removal of CPZ from the chow. The pattern of demyelination and spontaneous remyelination occurs over a highly expected time course and within anatomically distinct areas, and can be evaluated using microscopic analysis. However, there are no overt signs such as paralysis or other observable nervous system impairments resulting from the CPZ-induced demyelination.

**Theiler's murine encephalomyelitis virus model**

TMEV is a single-stranded RNA virus that is a member of the *Picomaviridae* family. In susceptible strains of mice, it induces early acute disease resembling polioencephalomyelitis followed by late chronic demyelinating disease. During early acute disease the virus replicates in gray matter of the CNS but is eliminated to very low titers 2 weeks post-infection. Late chronic demyelinating disease occurs 2 weeks later and is characterized by extensive demyelinating lesions and mononuclear cell infiltrates, progressive spinal cord atrophy, and axonal loss (Oleszak et al., 2004).

Intracranial inoculation of susceptible strains of mice with the Theiler’s DA strain induces biphasic disease, with early acute disease occurring within 3 to 12 days post-immunization (p.i.), followed by late chronic demyelinating disease at 30 to 40 days, and eventually causes the death of the animals (Oleszak et al., 1995; Dal Canto et al., 1996). Resistant strains of mice, such as C57BL/6, develop only slowly early acute disease, clear the virus completely in about 3 weeks p.i., and do not develop late chronic demyelinating disease (Lorch et al., 1981). Intracerebral infection of the C57BL/6 mouse strain causes acute seizures and epilepsy (DePaula-Silva et al., 2017).

**Pharmacological Therapies for Multiple Sclerosis-Type Disease**

The pharmacological therapies were with cerebrolysin, CTK 01512-2 (a calcium channel blocker), melatonin, naltrexone, diarylpropionitrile, ST266 (amnion cell secretome), trichostatin A, C-phycocyanin, siponimod, white grape juice extract, lanthionine ketamine ester, caffeine, adrenomedullin, glatiramer acetate (all in EAE mouse model); Pien Tze Huang (PZH), dihydrotestosterone, memantine hydrochloride, pregabaline (all in EAE rat model); bilobalide, linagliptin, BLZ945 (calcium channel blocker) 1 receptor kinase inhibitor), indomethacin (all in CPZ mouse model); recombinant human IgM12 antibody (in TMEV mouse model). There were fourteen studies using EAE mouse model and four studies using EAE rat model found in the PubMed search. All except three had used immunization with MOG<sub>35-55</sub> Peptide emulsified in Freund's adjuvant, supplemented in most studies with mycobacterium tuberculosis and receiving pertussis toxin. In addition, four studies using CPZ mouse model and one study using TMEV mouse model were found in the PubMed search. In the mouse studies, the ages of the animals at which treatment was started ranged from 7–17 weeks for those studies in which ages were reported, and where gender was specified 13 studies had used females and 3 studies had used males. In the rat studies, the ages of the animals at which treatment was started ranged from 7–13 weeks, and where gender was specified 2 had used females and 2 had used males.

**EAE animal studies**

**Cerebrolysin**

Treatment i.p. with cerebrolysin (low molecular weight neuropeptide(s) prepared from extract of porcine brain tissue, Ghaffarpasand et al., 2018) for 28 days of female C57BL/6 mice, 10–11 weeks of age in which EAE had been induced by MOG<sub>35-55</sub> immunization, decreased the average clinical scores compared to mice treated with saline. Cerebrolysin alleviated demyelination in optic nerves and cervical spinal cord. In addition, cerebrolysin alleviated neurofilament loss in cervical spinal cord and microglia density (ionized calcium binding adaptor molecule 1 (Iba-1) staining) in the medulla. In this study a relapsing-remitting pattern of the disease was observed. The beginning of hind limb deficits in EAE mice was observed 8–12 days p.i. with increasing clinical scores up to 14 days after the beginning of the initial impairments, after which the scores began to decrease (Toader et al., 2018).

**CTK 01512-2**

Treatment with CTK 01512-2 (a calcium channel blocker) (50 and 100 pmol/site) intrathecal (i.t.) on days 4, 10, 15, 20, and 24 p.i. of female C57BL/6 mice, 6–8 weeks of age in which EAE had been induced by MOG<sub>35-55</sub> immunization, delayed the onset of symptoms and reduced the clinical manifestations of EAE, prevented the body weight loss, and significantly decreased neurological impairment compared to EAE-vehicle mice. CTK 01512-2 (50 pmol/site, I.T., days 4, 10, 15, 20, 24) significantly reduced the levels of tumor necrosis factor (TNF), interleukin (IL)-1β, interferon (IFN)-γ, IL-17 and IL-23; the values were close to those observed in the naïve group for spleen, brain and spinal cord except for IL-1β in the spleen and IL-23 in the brain and spleen. Treatment with CTK 01512-2 (50 pmol/site, i.t., days 4, 10, 15, 20, 24) significantly increased IL-10 levels in the spleen, brain and spinal cord at 25 days p.i. compared to EAE-vehicle group. Also, CTK 01512-2 treatment (50 pmol/site) significantly decreased inflammation and demyelination in the lumbar spinal cord and inflammation in the brain at 25...
days p.i.. CTK 01512-2 (50 pmol/site) significantly reduced the level of astrocyte activation (glial fibrillary acidic protein (GFAP) marker) in the lumbar spinal cord and microglia activation (Iba-1) in the brain at 25 days p.i. compared to EAE-vehicle group. CTK 01512-2 treatment (50 pmol/site, i.t., days 4, 10, 15, 20) significantly decreased the neuroinflammatory process in all evaluated brain regions, except for the hippocampus, on day 23 p.i. Administration of CTK 01512-2 by intravenous route at 0.2 mg/kg every 3 days, starting on day 7 post-MOG35 injection, reduced all behavioral and non-behavioral parameters examined previously, and with a similar efficacy to i.t. route (Silva et al., 2018).

**Melatonin**

Female C57BL/6 mice, 8–10 weeks of age in which EAE had been induced by MOG35-55 immunization, were treated i.p. with melatonin on day 0 p.i. to the peak period of the disease. Melatonin significantly decreased the neurological deficit score compared to EAE-vehicle mice and significantly delayed the first neurological signs of disease and shortened the clinical symptomatic stage. Treatment with melatonin decreased the number of inflammatory lymphocytes infiltrating into the spinal cord compared to EAE-vehicle mice. Melatonin significantly decreased the levels of thiobarbituric acid reactive substance (TBARS) and reactive oxygen species (ROS) and significantly increased the levels of the antioxidant enzymes superoxide dismutase (SOD) and catalase (CAT) compared with EAE-vehicle mice. Treatment with melatonin significantly increased the expression of nuclear factor erythroid 2-related factor 2, and its related antioxidant enzymes heme oxygenase-1 and NAD(P)H: quinone oxidoreductase 1 in the spinal cord at the peak of disease (Long et al., 2018).

**Diarylpropionitrile**

Treatment s.c. with diarylpropionitrile (an estrogen receptor β ligand) was initiated at 1 week prior to EAE induction and on alternate days to female ovariectomized C57BL/6 mice, 8–12 weeks of age in which disease had been induced by MOG35-55 immunization. EAE mice treated with diarylpropionitrile exhibited alleviation of EAE during the chronic phase. Diarylpropionitrile protected axons in EAE mice as indicated by an increase in neurofilament 200 (NF200)+ axons and a decrease in non-phosphorylated NF200 (SMI32)+ and β-amyloid precursor protein (βAPP)+ axons in spinal cord white matter. Myelin in EAE mice was protected by diarylpropionitrile and the g-ratio was decreased, consistent with increased myelin. Diarylpropionitrile treatment decreased the proinflammatory phenotype of myeloid cells in the CNS during EAE, and increased the percentages of Olig2+GSTT1+ mature and Olig2+CC1+ immature/mature oligodendrocytes (Kim et al., 2018).

**Naltrexone**

Naltrexone (an opioid receptor antagonist) was administered i.p. for 14 days to female C57BL/6 mice, 7–8 weeks of age in which EAE had been induced by MOG35-55 immunization. Within 1 week p.i. and prior to observed clinical disease, EAE-PBS mice had significantly lower serum encephalin levels compared to controls. After 7 days of naltrexone treatment, EAE mice receiving naltrexone in the morning had significantly higher serum opioid growth factor (Mε-encephalin) when blood was collected in the morning and substantially less enkephalin in the serum when blood was collected in the afternoon. At week 3 (peak disease), treatment with naltrexone lowered the clinical score and increased serum enkephalin level compared to EAE-PBS mice. EAE mice injected with naltrexone for 7 days had a significant decrease in total leukocytes compared to mice receiving PBS. Naltrexone treated mice had significantly longer hot plate response at 7 days compared to EAE-PBS mice, but no difference at 2 or 3 weeks following a 7-day washout period. No difference was found in touch response over 3 weeks of testing between EAE-naltrexone and EAE-PBS mice (Ludwig et al., 2017).

**ST266**

Female C57BL/6 mice, 8 weeks of age in which EAE had been induced by MOG35-55 immunization, were treated intranasally with ST266 (secretome of amnion-derived multipotent progenitor cells) before onset of optic neuritis (day 1 to day 42) or after (days 15–30, 15–42, 22–42, and 30–42). ST266 treatment before the onset of optic neuritis significantly improved visual function of EAE mice. ST266 significantly decreased the loss of retinal ganglion cells and their axons in EAE mice at 6 weeks p.i. In addition, daily ST266 treatment significantly decreased inflammatory cell infiltration of optic nerve and significantly reduced the degree of demyelination induced by EAE optic neuritis at 6 weeks p.i. compared to EAE-vehicle mice. ST266 treatment initiated at day 15 significantly prevented retinal ganglion cell loss at day 42, and treatments started on day 22 or 30 showed a trend towards increased retinal ganglion cell survival. A small significant increase in retinal ganglion cell axon density was induced by ST266. Improved visual function and retinal ganglion cell survival in ST266 treated mice was associated with decreased optic nerve inflammation. Demyelination was also decreased in ST266 treated mice compared with vehicle treated mice. ST266 treatment started before or after onset of optic neuritis had little effect on ascending paralysis and related spinal cord inflammation and demyelination, consistent with the lower levels of ST266 that reach other parts of the CNS following intranasal delivery. ST266 treatment of EAE mice beginning on day 15 p.i. resulted in increased expression of NAD-dependent protein deacetylase sirtuin-1 (SIRT1) in the retina by day 22 compared to EAE-vehicle mice. This was associated with increased retinal and optic nerve levels of mitochondrial enzymes consistent with increased mitochondrial biogenesis in EAE-ST266 mice. In addition, ST266 treatment decreased ROS that accumulated in the optic nerve during optic neuritis (Khan et al., 2017).

**Trichostatin A**

Treatment s.c. 3 times/week for 8 weeks with trichostatin A (an inhibitor of histone deacetylase) of female NOD/ShiLtJ

**Kim et al., 2018.**

**Martinez B, Peplow PV (2020) Protective effects of pharmacological therapies in animal models of multiple sclerosis: a review of studies 2014–2019. Neural Regen Res 15(7):1220-1234. doi:10.4103/1673-5374.272572**
mice, 9 weeks of age in which EAE had been induced by MOG35-55 immunization, substantially decreased the clinical severity of the disease and protection was found after 9 weeks of trichostatin A cessation. The sustained disease course without pronounced remissions is similar to primary progressive MS. Trichostatin A treatment during the first 2 weeks of immunization was sufficient to lessen the progression of EAE. Also established EAE in NOD mice could be reversed by trichostatin A treatment started after the onset of severe disease (clinical score > 2.0) on day 15 and continued up to 45 days. The clinical score was decreased as soon as 5 days after the first dose of trichostatin A given therapeutically and protection lasted for at least 5 weeks following trichostatin A termination. Prophylactic treatment with trichostatin A significantly decreased the inflammation of the spinal cord both during the early (28 days) and chronic stage (54 days) and prevented demyelination and loss of axons during the chronic stage of the disease on day 54. Trichostatin A treatment reduced the infiltration of Th1 cells in NOD mice. During the late phase of the disease (97 days), in addition to Th1 cells, Th17 cells as well as those producing granulocyte-macrophage colony stimulating factor (GM-CSF) appeared in the spinal cord. Trichostatin A treatment decreased the frequency of the T cells infiltrating the CNS regardless of their lymphohkine profiles, and mitigated neuronal damage (Jayaraman et al., 2017).

**C-Phycocyanin**

Female C57BL/6 mice, 6–8 weeks of age in which EAE had been induced by MOG35-55 immunization, were treated i.p. with C- phycocyanin at disease onset for 15 days. C-Phycocyanin treatment appeared to decrease disease severity in EAE mice with maximum clinical scores lowered in mice treated with C- phycocyanin 4 mg/kg per day and 8 mg/kg per day. Mice treated with C- phycocyanin 4 mg/kg per day and 8 mg/kg per day had a significant reduction in the number of inflammatory foci present in the spinal cord at day 29 p.i. A significant reduction of the extent of white matter demyelination in the spinal cord was also identified in Luxol fast blue (LFB)-periodic acid Schiff (PAS) staining for C- phycocyanin doses 4 and 8 mg/kg per day. In Mac-3 staining for activated macrophages/microglia, there was a significant reduction of these cells in the lesions of C- phycocyanin 8 mg/kg per day treated EAE mice compared to vehicle treated EAE mice. At C- phycocyanin 4 mg/kg per day, there was a tendency for a reduction compared to the EAE vehicle group. However, C- phycocyanin 4 mg/kg per day treatment effectively counteracted axonal degeneration in EAE mice while there was only a tendency for a reduction with C- phycocyanin 8 mg/kg per day treatment. C- Phycocyanin treatment 8 mg/kg per day reduced the levels of oxidative stress parameters malondialdehyde, peroxidation potential, and CAT/SOD ratio, and significantly increased reduced glutathione (GSH) levels in blood lysates taken at day 15 p.i. In addition, C- phycocyanin treatment 8 mg/kg per day significantly decreased the relative expression of IL-17 mRNA and IL-6 mRNA in the brain compared to EAE vehicle animals at day 18 p.i. A set of genes associated with the remyelination process was upregulated by C- phycocyanin: Mal, Mog and Mobp, which are structural components of the myelin sheath; a transcription factor Olig1 present exclusively in oligodendrocytes; Nkx6-2 and Nkx2-2 genes related to the axon-glial interactions; and Bmp, involved in the processes of gliogenesis. Additionally, C- phycocyanin significantly decreased the expression of genes involved in the process of demyelination such as CD44 and PPAR (Pentón-Roll et al., 2016).

**Siponimod**

C57BL/6 mice were immunized with MOG35-55 to induce EAE and 1 week prior to immunization received continuous intracerebroventricular (i.c.v.) infusion of siponimod for 4 weeks. Treatment with siponimod 4.5 µg/day significantly decreased the number of T lymphocytes in the blood of EAE-induced mice compared to EAE-vehicle mice at 18 days p.i., during the symptomatic phase of the disease. Siponimod 4.5 µg/day completely inhibited EAE development in treated mice compared to EAE-vehicle mice, suggesting that the effects of siponimod on peripheral lymphocytes mediated its disease-modifying activity when administered at this daily concentration. A siponimod dose of 0.45 µg/day had comparable effects on peripheral lymphocytes and significantly alleviated disease severity on days 21–24 p.i. compared to EAE-vehicle mice. In coronal striatal slices, the levels of GFAP (marker of astrocyte activation) and Iba-1 (marker of microglia/macrophage) were significantly decreased in EAE mice treated with siponimod 0.45 µg/day, as well as a decrease in the number of infiltrating lymphocytes. Quantitative analysis of Iba-1 mRNA and CD3 mRNA by qPCR confirmed significantly decreased microglia activation and lymphocyte infiltration in the striatum of EAE mice receiving siponimod compared to EAE-vehicle mice. Siponimod reduced GABAergic interneuron loss in the striatum of symptomatic EAE mice (Gentile et al., 2016).

**White grape juice extract**

Male C57BL/6 mice, 6–9 weeks of age in which EAE was induced by MOG35-55 immunization, were treated p.o. with white grape juice extract (WGJe) given 1 week before EAE induction and continued until day 21. Mice treated daily with WGJE 40 mg/kg showed only slight signs of the disease (clinical score 0.9), while those receiving WGJe 20 mg/kg per day had decreased severity of disease (clinical score 2.4, compared to clinical score 4.8 for EAE control mice). An increase in body weight occurred in EAE mice receiving WGJe 40 mg/kg per day. A significant infiltration of T lymphocytes, monocytes and neutrophils was observed in the white matter of the spinal cord of EAE mice and demyelinating plaque formation. Treatment with WGJe 40 mg/kg per day significantly protected against EAE changes and a slight preventive effect occurred in WGJe 20 mg/kg per day treated mice in which there were some cells and leukocytes infiltrated areas of demyelination. High levels of TNF-α staining were observed in spinal cord tissues of EAE mice, but no positive staining for TNF-α was found in spinal cord tissues of mice treated with
WGJe 20 or 40 mg/kg per day. A positive staining for nitrotyrosine (marker of oxidative stress) in spinal cord sections of EAE mice was found; treatment with WGJe significantly lowered the level of nitrotyrosine, with a dose of 40 mg/kg per day more effective than 20 mg/kg per day. WGJe at 20 mg/kg per day significantly decreased inducible nitric oxide synthase (iNOS) expression caused by EAE and no positive staining was observed for iNOS in WGJe 40 mg/kg per day treated mice. Regulatory T cells (Treg) are characterized by the expression of transcription factor Fork head box P3 (Foxp3). Spinal cord sections from EAE mice showed positive staining for Foxp3 but was not observed in WGJe 20 mg/kg per day and 40 mg/kg per day treated mice. A pronounced presence of apoptotic cells was identified in spinal cord sections of EAE mice using TUNEL staining. The number of apoptotic cells was reduced in WGJe 20 mg/kg per day treated mice, and none were observed in WGJe 40 mg/kg per day treated mice. While no staining for Bcl-2 could be detected in spinal cord sections of EAE mice, positive staining was observed for WGJe 20 mg/kg per day and 40 mg/kg per day treated mice. Spinal cord sections of EAE mice had high levels of expression of caspase 3 and this was prevented by treatment with WGJe 20 mg/kg per day and 40 mg/kg per day (Giacoppo et al., 2015).

**Lanthionine ketamine ester**

Female C57BL/6 mice, 8 weeks mean age in which EAE was induced by MOG35-55 immunization, were provided with lanthionine ketamine ester (LKE) 0.01% (w/w) in chow giving an average daily dose of 8 mg/kg beginning on day 36 p.i. and continued to day 57 p.i. Mice treated with LKE showed significant clinical recovery over this period with the average clinical score decreased from 2.3 to 1.3. Total neurodegeneration in the optic nerve and spinal cord of EAE mice was significantly reduced by LKE treatment. Treatment with LKE significantly decreased the percentage of axons with abnormal mitochondria and loss of contact in the optic nerve, and significantly decreased axons with condensation in the spinal cord. From EM images of the optic nerve there was a significant increase in myelin thickness and axon caliber in LKE-treated mice versus vehicle-treated mice. In the spinal cord, LKE treatment significantly increased myelin thickness compared to vehicle-treated EAE mice. No significant change in g-ratio due to LKE treatment occurred in either the optic nerve or spinal cord. While LKE treatment had modest, non-significant effects on CRMP2 and pCRMP2, the ratio of pCRMP2:CRMP2 which was greatly increased in the EAE mice was significantly lowered by LKE treatment (Dupree et al., 2015).

**Caffeine**

Treatment with caffeine 30 mg/kg per day in drinking water of female C57BL/6 mice, 8–10 weeks of age in which EAE had been induced by MOG35-55 immunization, was performed over different time periods. The caffeine (0–10)-EAE group that received caffeine during the induction phase (0–10 days p.i.) showed a trend of worse neurological deficits and higher EAE scores and a relatively early peak of the neurological deficit compared to the water-EAE group, but was not statistically significant. By contrast, the caffeine (10–20)-EAE group received caffeine treatment at the effector phase (10–20 days p.i.) and had significantly decreased neurological deficits compared to the water-EAE group, with reduced maximal deficit score and relatively delayed disease onset. The most significant protection was found in the caffeine (−10–20)-EAE group that received caffeine for the entire course. Caffeine treatment given immediately prior to MOG immunization (i.e. −10–0 days p.i.) was not effective in modifying the disease development. Mice in the water-EAE group showed extensive entry of inflammatory cells into the spinal cord, and mice in the caffeine (0–10)-EAE group also showed inflammatory cell infiltration. Caffeine treatment for the entire EAE course (i.e. −10–20 days p.i.) protected against EAE pathology, with reduced infiltration of inflammatory cells into the spinal cord in association with decreased neurological deficits. Caffeine treatment at the effector phase (i.e. 10–20 days p.i.) significantly protected against EAE pathology, while caffeine treatment at the induction phase (i.e. 0–10 days p.i.) was not effective. While 10 days of caffeine treatment in caffeine (−10–0)-EAE, caffeine (0–10)-EAE, and caffeine (10–20)-EAE groups did not produce significant neuroprotective effects against demyelination in the cerebral cortex, the intensity of LFB staining was significantly higher for 30 days caffeine treatment in caffeine (−10–20)-EAE group. Comparing the expression of proinflammatory cytokines in the cerebral cortex to the water-CFA group, IL-17 mRNA in the brain was increased in the water-EAE group, caffeine (−10–0)-EAE group, and caffeine (0–10)-EAE group, but caffeine treatment in the caffeine (10–20)-EAE group and caffeine (−10–20)-EAE group partially reversed this increase. Also the expression levels of IFN-γ mRNA in the brain were markedly increased in the water-EAE group and caffeine (0–10)-EAE group compared to the water-CFA group. The caffeine (−10–20)-EAE group had a significant lowering of the increase of IFN-γ, with caffeine (−10–0)-EAE group and caffeine (10–20)-EAE group showing similar reduction but without reaching statistical significance. The expression level of the anti-inflammatory cytokine transforming growth factor-β (TGF-β) was decreased in the water-EAE group compared to water-CFA group. Caffeine treatment in the caffeine (−10–20)-EAE group and caffeine (10–20)-EAE group significantly increased the TGF-β mRNA level in the brain compared to the water-EAE group (Wang et al., 2014).

**Adrenomedullin**

Female C57BL/6 mice, 8 weeks of age in which EAE was induced by MOG35-55 immunization, were treated i.p. for 5 consecutive days in mice with a clinical score of 0.5–1 (onset) or 1–1.5 or > 2 (acute phase). Disease incidence and severity were greatly decreased by treatment with adrenomedullin after the onset or during the effector phase of the disease. Most of the adrenomedullin-treated EAE mice showed mild symptoms and a significant number recovered completely.
and were entirely asymptomatic 30–40 days after disease course. A short treatment for 5 days with adrenomedullin was sufficient to produce a long lasting protective effect. Adrenomedullin treatment markedly decreased the number of plaques with inflammatory infiltrates and areas of demyelination in both the lumbar and cervical regions of the spinal cord compared to EAE-vehicle group. Immunofluorescence analysis of CNS infiltrates in EAE animals at peak of disease revealed that the inflammatory cells (CD45+) close to the perivascular area were mostly CD4+ cells and Iba-1+ macrophages. Treatment with adrenomedullin decreased the number of CD45+, CD4+, and Iba-1+ cells infiltrating the CNS and correlated with a significant decrease in the levels of inflammatory cytokines and chemokines including IL-6, IFN-γ, CCL5, CCL2, CCXCL2 in the spinal cords at peak of disease. Also, adrenomedullin treatment significantly decreased the levels of GM-CSF and osteopontin in the spinal cords at peak of disease, two inflammatory markers that play a major role in the induction and progression of EAE and MS. Adrenomedullin treatment significantly decreased the number of effector T cells secreting IFN-γ but not IL-17 in draining lymph nodes and spleen, and significantly increased the percentage of IL-4- and IL-10-expressing CD4 cells. Adrenomedullin administration increased the number and percentage of IL-10-secreting CD4+CD25+Foxp3+ Treg cells in draining lymph nodes and spleens of EAE mice. Despite lower numbers of CD4 T cells, adrenomedullin significantly increased the percentage of Foxp3+ cells in the CNS. Treg cells confer significant protection against EAE by deactivating autoreactive T cells and their homing to the CNS (Kohm et al., 2002; Bynoe et al., 2003). Adrenomedullin decreased the production of inflammatory cytokines TNF-α, IL-12, and IL-6 from cultures of lipopolysaccharide-activated astrocytes, microglia and neuron-glial isolated from newborn mice, and of NO by lipopolysaccharide/IFN-γ-activated microglia. Adrenomedullin significantly decreased cell death induced by oxidative stress in precursor and mature oligodendrocytes. The gene expression of neuroprotective factors such as brain-derived neurotrophic factor (BDNF) and activity-dependent neuroprotective protein (ADNP) in the spinal cords was significantly increased by treatment of EAE mice with adrenomedullin at disease onset (Pedreño et al., 2014).

**Glatiramer acetate**

C57BL/6 mice, 8 weeks of age in which EAE was induced by MOG35-55 immunization, were treated s.c. with glatiramer acetate 2 mg/day for 8 consecutive days beginning after the appearance of clinical disease (days ~12–15 p.i.) starting on day 16 (clinical score ~2, hind limb weakness) or day 21 (clinical score ~3, partial hind limb paralysis). Vehicle-treated EAE mice assumed a chronic, persistent EAE disability phenotype beginning at day ~20, as indicated by increased EAE clinical scores. Glatiramer acetate treatment started on day 16 caused a suppression of disease phenotype, with treated mice showing a pronounced decrease in EAE clinical scores. A significant but less pronounced and persistent decrease in EAE scores was observed when glatiramer acetate treatment was started on day 21. The persistent clinical benefit long after cessation of glatiramer acetate treatment indicated a durable response. Rotarod motor performance declined sharply as EAE clinical disability progressed, but glatiramer acetate treatment rescued performance within 10 days of treatment initiation (which was started on day 15 for females and day 18 for males). Increased 4′,6-diamidino-2-phenylindole+ cell infiltration (which includes inflammatory infiltrates) was observed in dorsal column of thoracic spinal cord sections of EAE-vehicle mice, and which was decreased by glatiramer acetate treatment initiated on day 21. CD3+ T cells were a major infiltrating cell population in vehicle-treated EAE spinal cords. Glatiramer acetate treatment significantly decreased T cell numbers in the spinal cord dorsal column of EAE mice. Activation of resident CD45+ CNS microglia occurred in EAE lesions, and a decrease of CD45+ CNS microglia was found in glatiramer acetate-treated EAE spinal cord dorsal column. GFAP astrogliosis was observed in both EAE groups, with a nonsignificant trend towards a decrease in the glatiramer acetate-treated group. The spinal cord dorsal column, a major myelinated ascending fiber tract, revealed a significant decrease in myelin basic protein (MBP) staining in vehicle-treated EAE mice compared to normal controls. The spinal cord dorsal column of glatiramer acetate-treated EAE mice had significantly greater MBP staining intensity compared to vehicle-treated EAE mice. By immunostaining mature myelin-producing oligodendrocytes for CC1, therapeutic glatiramer acetate induced an increase in CC1+ mature oligodendrocyte cell numbers. Analysis using Olig2 of all oligodendrocyte lineage cells including oligodendrocyte progenitors showed a decrease in Olig2+ cells in vehicle-treated EAE spinal cord dorsal column and a reversal of this effect in glatiramer acetate-treated EAE spinal cord dorsal column. Glatiramer acetate treatment significantly decreased the pronounced axonal loss (as measured by NF200+ staining) observed in vehicle-treated EAE spinal cord (Moore et al., 2014b).

**Pien Tze Huang**

Male Lewis rats, 9–11 weeks of age in which EAE was induced by immunization with guinea pig MBP, were treated intragastrically with PZH daily for 3 weeks from day 10 p.i. (EAE disease onset). PZH 0.162 g/kg and 0.486 g/kg decreased the clinical score especially in the remission phase. Treatment with PZH markedly reduced the extent of inflammatory lesions in the brain, brainstem, and spinal cord. PZH 0.162 g/kg and 0.486 g/kg significantly decreased the levels of the proinflammatory cytokines and chemokines IL-17A, IL-23, CCL3, and CCL5 in the spinal cord and serum compared to EAE-vehicle rats. Furthermore, the levels of p-P65 and p-STAT3 in the spinal cord were significantly decreased by PZH 0.162 g/kg and PZH 0.486 g/kg compared to EAE-vehicle rats. Treatment with PZH 0.162 g/kg and 0.486 g/kg significantly increased the Olig2 and MBP levels in the brain compared to EAE-vehicle rats (Qiu et al., 2018).

Martinez B, Peplow PV (2020) Protective effects of pharmacological therapies in animal models of multiple sclerosis: a review of studies 2014–2019. *Neural Regen Res* 15(7):1220-1234. doi:10.4103/1673-5374.272572
**Dihydrotestosterone**

Treatment of male Dark Agouti rats, 7–9 weeks of age in which EAE was induced by inoculation with syngenic spinal cord homogenate, with dihydrotestosterone 1 mg s.c. on alternate days from the day after EAE induction changed the disease course after the peak (on day 14–15 p.i.), decreasing the clinical score from day 16 until the end of the study (day 45 p.i.). In addition, the weight of the rats recovered faster in EAE-dihydrotestosterone rats compared to EAE-vehicle rats. At 45 days p.i., dihydrotestosterone levels in spinal cord were significantly higher in EAE-dihydrotestosterone rats compared to EAE-vehicle rats, but there was no difference in the levels of its direct metabolites, 3α-diol or 3β-diol. These results suggested that the effect on clinical score of dihydrotestosterone treatment was not mediated by conversion into 3α-diol or 3β-diol. At 45 days p.i. there are few CD3+ (T cells) and ED1+ cells (activated macrophages) present in the spinal cord of EAE-Dark Agouti rats (Giatti et al., 2013). Therefore, at this stage neuroinflammation seems to be mainly sustained by resident cells. Spinal cord sections revealed that GFAP staining (marker of astrocytes) was significantly increased in EAE-vehicle rats compared to control rats. Dihydrotestosterone treatment significantly decreased GFAP staining compared to EAE-vehicle rats, with the levels being similar to control animals. MHC-II immunoreactive cells (microglia/macrophages) were significantly increased in the white matter of spinal cord of EAE-vehicle rats compared to control animals, and these cells showed a reactive morphology with some of them exhibiting amoeboid forms characteristic of highly activated states. Dihydrotestosterone treatment significantly reduced MHC-II staining and the reactive phenotype of MHC-II immunoreactive cells. Transcription analysis of TSPO gene in the spinal cord indicated a significant increase in EAE-vehicle rats compared to control animals and a significant decrease following dihydrotestosterone administration.

Dihydrotestosterone treatment significantly decreased the transcription of the proinflammatory cytokine IL-1β in the spinal cord, and also significantly decreased the transcription of both Toll-like receptor 4 and the p50 subunit of nuclear factor kappa B (NF-κB) which are two factors involved in IL-1β expression. Treatment with dihydrotestosterone significantly decreased TBARS in the spinal cord compared to EAE-vehicle rats, indicating an amelioration of oxidative stress. Dihydrotestosterone treatment reversed the lowering of mtDNA levels observed in the spinal cord of EAE-vehicle rats (Giatti et al., 2015).

**Memantine hydrochloride**

Female Brown Norway rats, 8–10 weeks of age in which EAE was induced by MOG35-55 immunization, were treated i.p. with memantine hydrochloride on alternate days starting on the day of immunization. EAE disease onset was significantly delayed in the rats treated with memantine 60 mg/kg compared to rats receiving vehicle. EAE rats receiving vehicle developed clinical signs on day 15.6 ± 0.7, memantine 20 mg/kg treated rats developed signs on day 17.0 ± 0.8, and the first neurologic signs appeared in memantine 60 mg/kg treated rats on day 23.5 ± 5.5. Clinical scores were significantly lower in both memantine groups. Disease incidence for immunized rats treated with vehicle was 67%, while for memantine 20 mg/kg and 60 mg/kg treated rats it was 45% and 25%, respectively. Levels of TNF-α and TGF-β1 in sera on day 8 of EAE were significantly increased in the EAE-vehicle group compared to normal controls, but no significant differences in TNF-α or TGF-β1 were found for the memantine treatment groups. The extent of demyelination of the optic nerve on day 8 of EAE was significantly decreased in both EAE-memantine groups compared to EAE-vehicle group. Also, the degree of inflammatory infiltration was significantly reduced in both EAE-memantine groups compared to EAE-vehicle group, with significantly lower numbers of CD3+ cells and ED1+ cells per square millimeter in whole optic nerve cross section in both EAE-memantine groups compared to EAE-vehicle group. Axonal loss was significantly lower in both EAE-memantine groups compared to EAE-vehicle group. In the axons remaining at this time point, there was a tendency toward decreased ßAPP deposition in the memantine 60 mg/kg group, but not in the 20 mg/kg group, compared to EAE-vehicle group. An anti-pan-neurofilament antibody was used to further investigate differences in surviving axons between treatment groups. Axonal densities were increased in the memantine-treated groups, especially the 60 mg/kg treatment group (Sühs et al., 2014).

**Pregabalin**

Pregabalin 30 mg/kg per day was administered p.o. to female Lewis rats, 7–8 weeks of age in which EAE was induced by immunization with MBP, starting immediately and continued until the time the animals were euthanized. Treatment with pregabalin delayed the onset of clinical signs compared to the vehicle treated group. Immunostaining of synaptophysin around the motoneuron cell bodies at lamina IX of the ventral horn of spinal cord showed that pregabalin treatment preserved presynaptic terminals in apposition to motoneurons. Iba-1 immunolabeling was used to assess the microglial reactivity as well as the infiltration of macrophages derived from monocytes to the spinal cord microenvironment. Microglia at lamina IX of Rexed (motor nucleus) showed a decrease in reactivity in response to pregabalin treatment, restricted to the exacerbation phase of EAE. A significant increase in the number of activated macrophages during peak disease in EAE-vehicle rats was found compared to normal rats, with the motoneurons surrounded by such cells. Treatment with pregabalin significantly decreased the microglial response. In the remission phase, a general reduction of Iba-1 immunoreactivity was detected in all groups. However, both EAE-vehicle and EAE-pregabalin groups showed significantly higher expression of Iba-1 compared to normal controls. GFAP immunolabeling was used to evaluate astroglial reactivity during the course of the disease. In the exacerbation phase during peak disease, there was a significant decrease of GFAP labeling of EAE-pregabalin group and normal controls compared to EAE-vehicle group.
with no significant difference between normal controls and EAE-pregabalin group. In the remission phase, the GFAP labeling of both the EAE-vehicle and EAE-pregabalin groups was significantly higher than the normal controls, with no significant difference between EAE-vehicle and EAE-pregabalin groups. Treatment with pregabalin did not significantly alter the levels of IL-6, IL-10, IL-27 and TGF-β in lymph nodes from the inguinal region, indicating a non-immunomodulatory role of pregabalin (Silva et al., 2014).

**Cuprizone animal studies**

**Bilobalide**

Male C57/BL6 mice, 11–13 weeks of age, were fed 0.2% (w/w) CPZ in chow diet for 6 weeks to induce acute demyelination, and after CPZ feeding for 4 weeks were treated i.p. with bilobalide 40 mg/kg per day for 2 consecutive weeks during CPZ feeding. The CPZ diet significantly increased touchdown time and decreased the percentage of time in the open arm compared to normal mice in both the pole test and elevated plus maze test. Bilobalide administration significantly improved behavioral performance of CPZ mice. The demyelination induced by CPZ was assessed by LFB, Black Gold II and MBP staining of corpus callosum of the brain after CPZ feeding for 4 weeks, and the intensity of staining was significantly decreased in CPZ-fed mice compared to normal mice. Bilobalide treatment of CPZ mice significantly increased the intensity of staining for myelin compared to CPZ-saline mice. The MBP expression and O4+ mature oligodendrocytes were decreased in the brain of CPZ-fed mice compared with normal mice. Bilobalide treatment significantly increased MBP expression and O4+ oligodendrocytes compared to CPZ-saline mice. CPZ-fed mice exhibited splenic atrophy and decreased splenic weight compared to normal mice. Bilobalide treatment increased the volume of the spleen and significantly increased the weight of the spleen compared to CPZ-saline mice. As oligodendrocytes are the main target cells in the CPZ model, MOG35–55 specific antibody was measured in serum, supernatant of cultured splenocytes and brain extract from CPZ mice. MOG35–55 specific antibody was significantly increased in serum, supernatant of cultured splenocytes and brain extract from CPZ-saline mice compared to normal mice. MOG35–55 specific antibody in serum, supernatant of cultured splenocytes and brain extract from CPZ-saline mice compared to normal mice. Male C57BL/6 mice, 6 weeks of age, were fed 0.7% (w/w) CPZ in chow for 7 days followed by 0.2% CPZ in chow. CPZ mice were treated p.o. with linagliptin 10mg/kg per day starting from the second week. Linagliptin treatment of CPZ mice significantly increased body weight and brain weight compared to CPZ-saline mice. CPZ mice showed behavioral and motor abnormalities as revealed by the open field, rotorod, and grip strength tests. Linagliptin treatment ameliorated these behavioral and motor abnormalities. CPZ-saline mice had significantly decreased MBP, PLP and Olig2 gene expression levels as well as significantly decreased LFB staining in corpus callosum sections compared to normal controls. Linagliptin treatment significantly increased MBP, PLP and Olig2 gene expression levels and LFB staining intensity in CPZ mice. In addition, CPZ-saline mice had a significant increase in TBARS level and a significant decrease in GSH content of the brain tissue compared to normal controls. Linagliptin treatment significantly decreased TBARS level and significantly increased GSH content of the brain tissue compared to CPZ-saline mice. CPZ feeding induced an inflammatory state as shown by a significant 4-fold increase in TNF-α level in the brain compared to normal controls. Linagliptin treatment significantly decreased brain TNF-α level compared to CPZ-saline mice. CPZ-saline mice had significant large increases in p-JAK2, p-STAT3 and NF-κB p65 protein expression levels compared to normal controls. Linagliptin treatment significantly decreased the p-JAK2, p-STAT3 and NF-κB p65 protein expression levels compared to CPZ-saline mice.

**Cuprizone animal studies**

**Bilobalide**

Male C57/BL6 mice, 11–13 weeks of age, were fed 0.2% (w/w) CPZ in chow diet for 6 weeks to induce acute demyelination, and after CPZ feeding for 4 weeks were treated i.p. with bilobalide 40 mg/kg per day for 2 consecutive weeks during CPZ feeding. The CPZ diet significantly increased touchdown time and decreased the percentage of time in the open arm compared to normal mice in both the pole test and elevated plus maze test. Bilobalide administration significantly improved behavioral performance of CPZ mice. The demyelination induced by CPZ was assessed by LFB, Black Gold II and MBP staining of corpus callosum of the brain after CPZ feeding for 4 weeks, and the intensity of staining was significantly decreased in CPZ-fed mice compared to normal mice. Bilobalide treatment of CPZ mice significantly increased the intensity of staining for myelin compared to CPZ-saline mice. The MBP expression and O4+ mature oligodendrocytes were decreased in the brain of CPZ-fed mice compared with normal mice. Bilobalide treatment significantly increased MBP expression and O4+ oligodendrocytes compared to CPZ-saline mice. CPZ-fed mice exhibited splenic atrophy and decreased splenic weight compared to normal mice. Bilobalide treatment increased the volume of the spleen and significantly increased the weight of the spleen compared to CPZ-saline mice. As oligodendrocytes are the main target cells in the CPZ model, MOG35–55 specific antibody was measured in serum, supernatant of cultured splenocytes and brain extract from CPZ mice. MOG35–55 specific antibody was significantly increased in serum, supernatant of cultured splenocytes and brain extract from CPZ-saline mice compared to normal mice. MOG35–55 specific antibody in serum, supernatant of cultured splenocytes and brain extract from CPZ-saline mice compared to normal mice. Linagliptin treatment ameliorated these behavioral and motor abnormalities. CPZ-saline mice had significantly decreased MBP, PLP and Olig2 gene expression levels as well as significantly decreased LFB staining in corpus callosum sections compared to normal controls. Linagliptin treatment significantly increased MBP, PLP and Olig2 gene expression levels and LFB staining intensity in CPZ mice. In addition, CPZ-saline mice had a significant increase in TBARS level and a significant decrease in GSH content of the brain tissue compared to normal controls. Linagliptin treatment significantly decreased TBARS level and significantly increased GSH content of the brain tissue compared to CPZ-saline mice. CPZ feeding induced an inflammatory state as shown by a significant 4-fold increase in TNF-α level in the brain compared to normal controls. Linagliptin treatment significantly decreased brain TNF-α level compared to CPZ-saline mice. CPZ-saline mice had significant large increases in p-JAK2, p-STAT3 and NF-κB p65 protein expression levels compared to normal controls. Linagliptin treatment significantly decreased the p-JAK2, p-STAT3 and NF-κB p65 protein expression levels compared to CPZ-saline mice.
mice. Also CPZ mice had significantly lower p-AMPK protein and SIRT1 gene expression levels compared to normal control mice. Linagliptin treatment significantly increased p-AMPK protein and SIRT1 gene expression levels compared to CPZ-saline mice (Elbaz et al., 2018).

**BLZ945**

Female C57BL/6 mice, 9–10 weeks of age, were fed 0.2% (w/w) CPZ in chow for 5 weeks to induce a pronounced demyelination together with a large involvement of microglia and astrocytes as observed by histology. CPZ mice were treated p.o. once per day with BLZ945 (colony-stimulating factor 1 receptor kinase inhibitor) at different doses. MBP and oligodendrocytes (glutathione S-transferase π, (GST-π) a marker for mature oligodendrocytes) were significantly decreased in cortex/striatum after 5-week CPZ-ingestion compared to normal controls, and 169 mg/kg per day BLZ945 treatment for 2 weeks after 5-week CPZ-ingestion significantly increased MBP and GST-π in the cortex/striatum. In corpus callosum/external capsule there was a significant decrease in MOG, GST-π, as well as myelin (LFB staining) in CPZ-vehicle group compared to controls, but no difference following 2 weeks of BLZ945 treatment. Thus, BLZ945 treatment enhanced remyelination and increased the number of mature oligodendrocytes in cortex and striatum but not in corpus callosum/external capsule of CPZ mice. Microglia and astrocytes were highly activated and significantly increased after 5-week CPZ-induced demyelination in cortex, striatum and corpus callosum/external capsule. A 2-week therapeutic treatment with BLZ945 significantly decreased the number of Iba-1+ microglia in cortex, striatum and corpus callosum/external capsule compared to CPZ-vehicle mice. BLZ945 treatment for 2 weeks after CPZ feeding significantly increased the number of GFAP+ astrogliosis in cortex, striatum and tended to increase the number in corpus callosum/external capsule compared to CPZ-vehicle mice. Microgliosis size, microglia form factor, and microglia activation were mostly increased after CPZ in all brain areas examined. These microgliosis parameters in cortex and striatum were further increased by therapeutic BLZ945 treatment, revealing a higher morphological activation status of the remaining microglia. These parameters were not changed at all or even decreased in corpus callosum and external capsule. To assess the effect of BLZ945 given prophylactically, mice were treated with 169 mg/kg per day BLZ945 p.o. for 1 week before as well as during the 5-week CPZ feeding period. CPZ-vehicle mice showed the expected demyelination (LFB staining) and increase of microglia (Iba-1) in the corpus callosum and external capsule compared to normal controls. BLZ945 treatment significantly increased myelin and decreased Iba-1+ microglia in the corpus callosum and external capsule compared to CPZ-vehicle mice. In addition, a significantly increased number of oligodendrocytes was detected in the corpus callosum in CPZ-BLZ945 mice compared to CPZ-vehicle mice, but a non-significant increase in the external capsule. No significant difference of SMI312+ axon fibers was observed in corpus callosum of CPZ-BLZ945 mice compared to CPZ-vehicle mice, whereas a significant decrease was observed in the external capsule. In the external capsule, Iba-1+ microglia were significantly slightly decreased in number, but a significant increase in myelin debris accompanied by a significant decrease in axonal fibers (SMI312) was detected in CPZ-BLZ945 mice compared to CPZ-vehicle mice. In the cortex, similar observations of increased myelin debris, axonal pathology and decreased NeuN+ cells in CPZ-BLZ945 mice were made (Beckmann et al., 2018).

**Indomethacin**

C57BL/6 mice were fed 0.2% (w/w) CPZ in chow for 10 weeks to induce demyelination in the corpus callosum, then fed normal chow and treated i.p. with 2.5 mg/kg per day indomethacin for up to 2 weeks. Mice that received indomethacin treatment after cessation of CPZ diet showed significantly increased levels of Cnp, Mag, Mbp and Pgp1 genes in corpus callosum during the remyelination phase compared to mice injected with vehicle alone. This was associated with higher numbers of NogroA+ mature oligodendrocytes, increased remyelination (LFB/PAS), higher numbers of Caspr2 paranodes and increased numbers of myelinated axons as indicated by electron microscopy. The g-ratio was significantly decreased in indomethacin-treated mice compared to vehicle-treated mice after 1 week of treatment suggesting enhanced remyelination. There were no differences in the total number of oligodendroglial lineage cells (oligodendroglial progenitor cells and mature oligodendrocytes) expressing Olig2 or in the number of proliferating Olig2+ cells between the two treatment groups. Axonal damage was examined by staining for amyloid precursor protein (APP) that accumulates in transected axons as well as in axons with a disturbed axonal transport. After 10 weeks of demyelination, as well as during remyelination, low numbers of APP+ axons were detected. Indomethacin treatment did not affect the numbers of damaged APP+ axonal spheroids or the numbers of astrocytes or microglia. The influence of indomethacin on several M1 or M2 markers expressed by microglia was investigated and no M2 shift in vivo was found (Presnir et al., 2015).

**Theiler’s murine encephalomyelitis virus animal study rHlgM12**

SJL/J mice, 8 weeks of age, received intracerebral injection of 2.0 × 105 plaque-forming units of Daniel’s strain TMEV. At 45 days post infection, the time point when demyelination in the spinal cord is well established and before substantial axon loss, SJL mice were treated with a single i.p. dose of 0.25, 2.5, 10, or 20 mg rHlgM12/kg. Improved horizontal nocturnal motor function in rHlgM12-treated mice became statistically significant on days 6, 9, and 14 post-treatment for 0.25, 2.5, 10, and 25 mg/kg doses, respectively, compared to control IgM. Improved horizontal nocturnal motor function of rHlgM12-treated mice persisted until the end of the study at 8 weeks. Improved vertical nocturnal motor function in rHlgM12-treated mice became statistically significant at days 12, 15, and 23 post-treatment for 2.5, 10, and 25 mg/kg.
doses, respectively, compared to control IgM. In a retrograde labeling study, SJL mice at 90 days post infection, the time point when axonal degeneration is present and progressing, were treated with a single i.p. dose of 10 mg rHIgM12/kg \((n = 9)\). At 9 weeks post treatment, retrograde labeling was performed using the tracer, Fluoro-Gold. There were fewer fluorescently labeled neuron cell bodies in the brainstem of TMEV mice compared to uninfected mice. The average number of labeled neurons in TMEV-rHIgM12 mice was significantly higher than in the TMEV-saline group. At 10 weeks post-treatment, significantly more axons were found in the spinal cord in the rHIgM12-treated group compared to the saline-treated group (Wootla et al., 2016).

### Disease-Modifying Effects of Pharmacological Agents

#### Experimental autoimmune encephalomyelitis animal studies

Different profiles of disease were identified among the various EAE studies reviewed. In the mouse studies, many had identified a chronic progressive type of EAE disease from the daily clinical scores that was similar to progressive MS (Moore et al., 2014b; Pedreño et al., 2014; Dupree et al., 2015; Jayaraman et al., 2017; Kim et al., 2018; Silva et al., 2018). However, some studies showed a relapsing-remitting pattern of disease (Pentón-Rol et al., 2016; Toader et al., 2018). It has been suggested that the MOG\(_{35-55}\) peptide dose may influence the course of the disease in C57BL/6 mice with a large dose of peptide and adjuvant causing a non-remitting EAE form, while a small dose induces relapse-remitting disease (Berard et al., 2010). Some of the mouse studies had examined the effects of certain pharmacological agents on optic neuritis. In the rat studies, a chronic progressive disease was induced by immunization with rat MOG\(_{1-135}\) peptide (Sühs et al., 2014), while immunization with MBP led to a peak of disease followed by a marked decline, reaching baseline clinical score (Silva et al., 2014; Qiu et al., 2018), and immunization with syngenic spinal cord homogenate caused a protracted relapsing course of the disease with all rats having at least one relapse during the follow-up period (Giatti et al., 2015).

In the EAE mouse studies all of the pharmacological agents tested, except for ST266 administered intranasally, caused a significant lowering of clinical scores when administered therapeutically, and some delayed the onset of disease (e.g. melatonin). Noteworthy, siponimod 4.5 μg/day administered i.c.v. completely inhibited EAE development, and a significant number of EAE mice receiving adrenomedullin 1 nmol/day i.p. for 5 consecutive days recovered completely and were asymptomatic 30–40 days after disease course. In addition, some agents were able to exert protection against chronic progressive EAE disease when administered prophylactically (e.g. trichostatin A).

In the EAE rat studies, PZH, dihydrotestosterone and memantine hydrochloride caused a significant lowering of clinical scores when administered therapeutically, and memantine hydrochloride and pregabalin delayed the onset of clinical signs. Interestingly, the incidence of disease was considerably lower in rats treated with memantine hydrochloride 60 mg/kg (started on the day of immunization with MOG) than in animals receiving vehicle (25% and 67%, respectively).

The disease-modifying effects of the agents in the EAE mouse and rat studies are summarized in Table 1, and included protection by preventing/reducing axonal, neuronal, myelin and oligodendrocyte damage, apoptosis, oxidative stress, excitotoxicity, infiltration of inflammatory cells, and proinflammatory cytokines/chemokines.

#### Cuprizone mouse studies

These studies examined whether the pharmacological therapies tested were able to promote remyelination when administered therapeutically to CPZ-fed mice, or prevent demyelination and oligodendrocyte loss when given prophylactically. The disease-modifying effects of therapeutic administration of these agents are summarized in Table 1. Prophylactic administration of BLZ945 resulted in increased myelin and decreased microglia in the corpus callosum and external capsule, increased number of oligodendrocytes in the corpus callosum, and decreased number of microglia in the external capsule.

#### Theiler’s murine encephalomyelitis virus mouse study

This study examined pharmacological therapy in a model with a progressive form of demyelination. The effects of therapeutic administration of monoclonal antibody rHIgM12 were improved nocturnal motor activity, increased neuron cell bodies in the brainstem, and increased number of axons in the spinal cord (Table 1).

### Future Perspectives

Two pathogenic processes are responsible for the neurological deficits in MS patients: acute inflammatory demyelination and axonal degeneration. The disability caused by inflammatory demyelination clinically dominates the early stages of relapsing-remitting MS and is reversible. Once a certain level of axonal degeneration is exceeded, MS patients enter an irreversible secondary progressive stage. In secondary progressive MS, axonal loss is caused by chronic demyelination and may be irreversibly progressive (Trapp et al., 1999). Disease-modifying drugs currently in use for MS suppress the immune system and reduce relapse rates but are ineffective in the progressive phase of the disease. For example, in clinical trials it was found that IFN-β significantly decreases the annualized relapse rates and the appearance of new brain lesions in relapsing-remitting MS, but has little or no effect on established progressive MS (Annibali et al., 2015). Moreover, about 40% of MS patients have no or only a low response to IFN-β treatment (Rudick et al., 2004). Therefore, it is necessary to develop novel therapies that target more specifically the inflammatory demyelinating and neurodegenerative components of the disease (Pentón-Rol et al., 2016).

Various animal models of MS have been established and
Table 1 Disease-modifying effects of pharmacological agents in EAE, CPZ and TMEV animal models of MS

| Effect of pharmacological agent | Pharmacological agent |
|--------------------------------|-----------------------|
| **EAE mouse studies**          |                       |
| Improved behavioral performance| CTK 01512-2, glatiramer acetate |
| Alleviated demyelination of spinal cord | Cerebrolysin, CTK 01512-2, C-phycocyanin, lanthionine ketamine ester, adrenomedullin |
| Alleviated demyelination of optic nerve | ST266, lanthionine ketamine ester |
| Protected against demyelination of cerebral cortex | caffeine |
| Decreased the number of microglia in medulla | Cerebrolysin |
| Decreased inflammation in the brain and spinal cord by altering the balance of proinflammatory/anti-inflammatory cytokines | CTK 01512-2, C-phycocyanin, caffeine, adrenomedullin |
| Decreased astrocyte activation in the spinal cord and microglia activation in the brain | CTK 01512-2 |
| Decreased activated microglia/macrophages in the spinal cord | C-phycocyanin |
| Decreased the number of macrophages in CNS infiltrates | Adrenomedullin |
| Decreased infiltration of inflammatory cells into the spinal cord and optic nerve | Melatonin, ST266, trichostatin A, caffeine, adrenomedullin, glatiramer acetate |
| Decreased the numbers of infiltrating CD4 T cells into the brain, particularly of IFN-γ- and IL-17-producing Th1 and Th17 cells | Adrenomedullin |
| Increased the percentage of IL-10-secreting CD4+CD25+FoxP3+ Treg cells in the CNS | Adrenomedullin |
| Decreased the levels of oxidative stress in the brain and spinal cord | Melatonin, white grape juice extract |
| Decreased the levels of ROS in optic nerve during optic neuritis | ST266 |
| Decreased parameters of oxidative stress in blood lysates | C-phycocyanin |
| Decreased the number of injured axons in the spinal cord | Diarylpropionitrile |
| Decreased proinflammatory phenotype of myeloid cells in the CNS | Diarylpropionitrile |
| Increased the Olig2 and MBP levels in the brain | Pien Tze Huang |
| Decreased astrocytes in the spinal cord | Dihydrotestosterone |
| Decreased microglia/macrophages and their reactive phenotype in the white matter of the spinal cord | Pien Tze Huang |
| Decreased CD4+ T cell infiltration in the corpus callosum | Dihydrotestosterone |
| Decreased CD45+ activated microglia and CD3+ T cell infiltrates in the corpus callosum | Dihydrotestosterone |
| **EAE rat studies**             |                       |
| Decreased demyelination of the optic nerve | Memantine hydrochloride |
| Decreased inflammatory cell infiltration in the brain, brainstem, and spinal cord | Pien Tze Huang |
| Decreased inflammatory cell infiltration in the optic nerve | Memantine hydrochloride |
| Decreased proinflammatory cytokines and chemokines in the spinal cord | Pien Tze Huang, dihydrotestosterone |
| Increased the Olig2 and MBP levels in the brain | Pien Tze Huang |
| Decreased astrogliosis in the spinal cord | Dihydrotestosterone |
| Decreased microglia/macrophages and their reactive phenotype in the white matter of the spinal cord | Dihydrotestosterone |
| Decreased reactivity of microglia at lamina IX of ventral horn of the spinal cord in exacerbation phase of EAE | Pregabalin |
| Decreased astrocyte reactivity at lamina IX of ventral horn of the spinal cord in the exacerbation phase during peak disease | Pregabalin |
| Decreased oxidative stress in the spinal cord | Dihydrotestosterone |
| Decreased axonal loss in the optic nerve | Pien Tze Huang, dihydrotestosterone |
| Increased the percentage of axons with abnormal mitochondria and loss of contact in the optic nerve | Dihydrotestosterone |
| Decreased the number of axons with condensation in the spinal cord | Lanthionine ketamine ester |
| Decreased the ratio between MOG-specific IgG2a and IgG1 antibodies | Lanthionine ketamine ester |
| Increased MBP staining intensity in spinal cord dorsal column | Glatiramer acetate |
| Reversed a decrease in oligodendrocyte lineage cells in the spinal cord dorsal column | Glatiramer acetate |
| Decreased proinflammatory lesions in the corpus callosum | Glatiramer acetate |
| Decreased CD45+ activated microglia and CD3+ T cell infiltrates in the corpus callosum | Glatiramer acetate |
Table 1 Continued

| Effect of pharmacological agent | Pharmacological agent |
|--------------------------------|-----------------------|
| **CPZ mouse studies**          |                       |
| Improved behavioral performance| Bulobalide, linagliptin|
| Increased myelin in the corpus callosum | Bulobalide, linagliptin |
| Increased MBP and mature oligodendrocytes in the brain | Bulobalide |
| Decreased MOG35-55 specific antibody in serum and the brain | Bulobalide |
| Decreased infiltration of CD4+ T cells, CD68+ macrophages and B220+ B cells into the brain | Bulobalide |
| Decreased the number of microglia in the brain | Bulobalide, BLZ945 |
| Inhibited the activation of microglia or M1 polarization of microglia in the brain | Bulobalide |
| Decreased the levels of the proinflammatory cytokines IL-1β, IL-6 and TNF-α in the brain | Bulobalide, linagliptin |
| Decreased the migration and accumulation of microglia toward the myelin sheath in the corpus callosum, striatum and medullary septal nuclei | Bulobalide |
| Decreased oxidative stress in the brain | Linagliptin |
| Increased MBP-positive remyelination and mature oligodendrocytes in cortex/striatum | BLZ945 |
| Increased the numbers of mature oligodendrocytes, accelerated remyelination, and increased the numbers of myelinated axons | Indomethacin |
| **TMEV study**                 |                       |
| Improved nocturnal motor activity | rHlgM12 |
| Increased neuron cell bodies in the brainstem, and increased number of axons in the spinal cord | rHlgM12 |

ADNP: Activity-dependent neuroprotective protein; BDNF: brain-derived neurotrophic factor; CNS: central nervous system; CPZ: cuprizone; EAE: experimental autoimmune encephalomyelitis; GABA: gamma-aminobutyric acid; IFN-γ: interferon-γ; IL: interleukin; MBP: myelin basic protein; MOG: myelin oligodendrocyte glycoprotein; MS: multiple sclerosis; TMEV: Theiler’s murine encephalomyelitis virus; TNF-α: tumor necrosis factor-α.

proved useful in studying the disease process and response to different therapies. The EAE animal studies reviewed here have shown that a chronic progressive disease can be induced by immunization with appropriate amounts of MOG, mycobacterium tuberculosis, and pertussis toxin in Freund's adjuvant (Moore et al., 2014b; Pedreño et al., 2014; Dupree et al., 2015; Jayaraman et al., 2017; Kim et al., 2018; Silva et al., 2018). They have enabled specific pathological processes to be studied and modified at different stages of the disease by administration of pharmacological agents. For example, administration of glatiramer acetate on day 16 (at onset, mouse EAE) resulted in suppression of disease phenotype and a marked decrease in EAE clinical scores. Furthermore, initiation of glatiramer acetate treatment on day 21 brought about a significant and persistent decrease in clinical scores (Moore et al., 2014b). Adrenomedullin administered after the onset or during the effector phase of the disease greatly reduced disease incidence and severity. Most of the adrenomedullin-treated EAE mice showed mild symptoms and a significant number recovered completely and were entirely asymptomatic 30–40 days after disease course (Pedreño et al., 2014). In another study, EAE mice were provided with lanthionine ketamine ester in chow on day 36, at which time the progressive nature of the disease was well established, and showed significant clinical recovery up to day 57 with a marked decrease in clinical scores. Improvements in clinical signs were observed in mice that had moderate to severe clinical signs (scores of 3 or 4) and also in those with milder signs (scores of 1 or 2) (Dupree et al., 2015). Treatment with trichostatin A for 8 weeks starting at the peak of disease was shown to decrease the clinical severity during the period of protracted disease in EAE NOD mice (between days 82 and 115) and protection continued for 9 weeks after cessation of treatment (Jayaraman et al., 2017). Intrathecal administration of CTK 01512-2 on days 4, 10, 15, 20, and 24 following MOG immunization prevented the occurrence of symptoms associated with the progression of EAE (Silva et al., 2018). These studies have shown that the clinical manifestation of EAE disease can be prevented or reduced by treatment with certain pharmacological agents given prior to, at, or after peak disease, and for some of these agents have confirmed the findings of previous studies e.g. glatiramer acetate (Aharoni et al., 2008, 2011). The CPZ mouse studies reviewed have shown that a marked demyelination of the CNS was induced in this animal model and the pharmacological agents tested were able to promote remyelination and increase the number of oligodendrocytes, and improve behavioral performance when administered therapeutically (Preissner et al., 2015; Beckmann et al., 2018; Elbaz et al., 2018; Sui et al., 2019). Prophylactic treatment with BLZ945 also promoted remyelination and increased the number of oligodendrocytes in CPZ mice (Beckmann et al., 2018). In the TMEV mouse study, it was shown that rHlgM12 administration preserved motor function by protecting axons in this model of progressive MS (Wootla et al., 2016). Demyelination has been shown to contribute to axonal loss in MS (DeLuca et al., 2006). Neuroprotective strategies aim at preventing axonal and neuronal loss, myelin and oligodendrocyte damage and cell death in MS patients (Villoslada, 2016). If such findings can be translated to clinical practice, they have relevance for delaying the progression of disease in patients with relapsing-remitting MS, for reducing clinical severity in patients with progressive phenotypes of MS, and for treating patients with clinically isolated syndrome (CIS) to prevent progression to MS. A person with CIS, accompanied or not accompanied by MRI brain lesions that are similar to those seen in MS, has a 60–80% or 20% chance, respectively, of developing MS within several years (National Multiple Sclerosis Society). Of note is the recent approval by the US FDA to approve siponimod for treating adults with RRMS, SPMS, and CIS.

Where age and gender were reported, most of the stud-
ies had used young adult female animals. While this might be related to a higher prevalence of MS in female patients (Wallin et al., 2019), there is a need for additional studies to be performed with male animals especially using the EAE model of MS. Furthermore, studies are warranted using aged animals as chronic low-grade inflammation is an important contributor to various age-related pathologies and natural processes in aging tissues, including the nervous system (Franceschi and Campisi, 2014; Sanada et al., 2018). Also most animals used in research studies are bred and housed in clean holding facilities, and do not have the same bacteria, viruses and pathogens that humans have, making them less than ideal models to study human disease. It has been suggested that laboratory animals born to wild parents or kept with animals from pet shops may be a way of achieving a more humanlike immune response (Frederick, 2019).

While therapies with single pharmacological agents have been shown to have benefit in the various types of animal models of MS, it may be that a combination therapy may be more effective, especially using agents that target neuroinflammation and neurodegeneration. The utilization of other neuroprotective agents with an immunomodulator was suggested as a way of enhancing the effectiveness of current drugs in treating MS, and one possible suggested neuroprotective agent was pregabalin (Silva et al., 2014). Similarly, a reagent that protects axons without associated remyelination could be paired with an immunomodulatory or remyelination-promoting agent (Wootla et al., 2016). A combination treatment using an immunomodulatory agent tufsin and a drug promoting remyelination benzotriepine improved MS-like pathologies in both EAE and CPZ models (Thompson et al., 2018). The importance of oxidative stress in MS is becoming increasingly recognized (Mossakowski et al., 2015), and a combination therapy using an immunomodulator and an antioxidant drug has been investigated. Combination treatment with glatiramer acetate and epigallocatechin-3-gallate significantly delayed disease onset, strongly reduced inflammatory infiltrates in an EAE relapsing-remitting disease model (Herges et al., 2011) but not in an EAE progression disease mouse model (Janssen et al., 2015). Future studies should determine the effectiveness of combining agents shown to be effective singly in alleviating processes such as neuroinflammation, axonal loss, and oxidative stress in animal models of chronic progressive disease as they may exert synergistic effects, and may provide more effective therapies for patients with MS.

Author contributions: Both authors wrote the manuscript and approved the final manuscript.

Conflicts of interest: The authors declare no conflicts of interest.

Financial support: None.

Copyright license agreement: The Copyright License Agreement has been signed by both authors before publication.

Plagiarism check: Checked twice by iThenticate.

Peer review: Externally peer reviewed.

Open access statement: This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-Non-Commercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

References

Aharoni R, Elaim R, Stock A, Vainshtein A, Shezen E, Gal H, Friedman N, Arnon R (2000) Glatiramer acetate reduces Th-17 inflammation and induces regulatory T-cells in the CNS of mice with relapsing-remitting or chronic EAE. J Neuroimmunol 225:100-111.

Aharoni R, Hershkovitz A, Elaim R, Blumberg-Hazan M, Sela M, Bruck W, Arnon R (2008) Demyelination arrest and remyelination induced by glatiramer acetate treatment of experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 105:11585-11587.

Ambrivi M, Mechelli R, Romano S, Buscarinu MC, Forasierio A, Umeton R, Ruggiano VA, Orzi E, Coccia EM, Salvetti M, Ristori G (2015) IFN-β and multiple sclerosis: from etiology to therapy and back. Cytokine Growth Factor Rev 26:221-228.

Baxter AG (2007) The origin and application of experimental autoimmune encephalomyelitis. Nat Rev Immunol 7:904-912.

Beckmann N, Giorgetti E, Neuhaus A, Zurbruegg S, Accurt N, Smith P, Perdoux J, Perton L, Nash M, Desrayaud S, Wippl P, Fineau WF, Shimshek DR (2018) Brain-region specific enhancement of remyelination and prevention of demyelination by the CSF1R kinase inhibitor BLZ945. Acta Neuropathol Commun 6:9.

Berard JL, Wolak K, Fournier S, David S (2010) Characterization of relapsing-remitting and chronic forms of experimental autoimmune encephalomyelitis in C57BL/6 mice. Glia 58:434-445.

Blakemore WF, Franklin RJ (2008) Remyelination in experimental models of neuroinjured demyelination. Curr Top Microbiol Immunol 318:193-222.

Burrows DJ, McGown A, Jain SA, De Felice M, Ramesh TM, Sharrack B, Majid A (2019) Animal models of multiple sclerosis: from rodents to zebrafish. Multipl Scler 25:306-324.

Bynoe MS, Evans JF, Viret C, Janeway CA Jr (2003) Epitope-specific immunization with autoantigenic peptides induces T suppressor cells that prevent experimental allergic encephalomyelitis. Immunol 19:317-328.

Dal Canto MC, Kim BS, Miller SD, Melvold RW (1996) Theliier's murine encephalomyelitis virus (TMEV)-induced demyelination: a model for human multiple sclerosis. Methods 10:453-461.

DeLuca GC, Williams K, Evangelou N, Ebers GC, Estri MM (2006) The contribution of demyelination to axonal loss in multiple sclerosis. Brain 129:1507-1516.

DePaula Silva AR, Hanak TJ, Libbey JE, Fujimani RS (2017) Theliier's murine encephalomyelitis virus infection of SJL/J and C57Bl/6 mice: models for multiple sclerosis and epilepsy. J Neuroimmunol 308:30-42.

Dupree JL, Polak PE, Hensley K, Pelligrino D, Feinstein DL (2015) Lanthionine ketimine ester provides benefit in a mouse model of multiple sclerosis. J Neu-rochem 134:302-314.

Dutta R, Trapp BD (2011) Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis. Prog Neurobiol 93:1-12.

Elbar EM, Senousy MA, El-Tanbouly DM, Sayed RH (2018) Neuroprotective effect of linagliptin against cuprizone-induced demyelination and behavioural dysfunction in mice: A pivotal role of AMPK/SIRT1 and JAK2/STAT3/NF-κB signaling pathway modulation. Toxicol Appl Pharmacol 352:153-161.

Encinas JA, Lees MB, Soob RA, Symonowicz C, Weiner HL, Seidman CE, Seidman JG, Kuchroo VK (2001) Identification of genetic loci associated with paralysis, inflammation and weight loss in mouse experimental autoimmune encephalomyelitis. Int Immunol 13:257-264.

Franceschi C, Campisi J (2014) Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci 69(Suppl 1):S4-9.

Frederick E (2019) Could lab mice born to wild parents improve the search for human cures? Science. https://www.sciencemag.org/news/2019/08/could-lab-mice-born-wild-parents-improve-search-human-cures. Accessed 24 August 2019.

Gentile A, Musella A, Bullitta S, Fresengia D, De Vito F, Fantozzi R, Piras E, Gar-gano F, Borsellino G, Battistini L, Schubart A, Mandolesi G, Centonze D (2016) Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis. J Neuroimmunol 13:207.

Ghaffarpassand F, Torabi S, Rasti A, Niakan MH, Aghabakolou S, Pakzad F, Be-heshhti MS, Tabrizi R (2018) Effects of cerebrolysin on cerebral function in patients with traumatic brain injury: a systematic review and meta-analysis. Neuroschi-pait Diagn Treat 15:134.

Giacoppo S, Rigolio R, Romano S, Bucarini MC, Forasierio A, Umeton R, Ruggiano VA, Orzi E, Coccia EM, Salvetti M, Ristori G (2015) Multimodal analysis in acute and chronic experimental autoimmune encephalomyelitis. Acta Neuropathol Commun 3:256.

Giatti S, Ricigliano V A, Orzi F, Coccia EM, Salvetti M, Ristori G (2015) IFN-β and multiple sclerosis: from etiology to therapy and back. Cytokine Growth Factor Rev 26:221-228.

Gold R, Linington C, Lassmann H (2006) Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in multiple sclerosis. J Neuroimmunol 175:100-111.

Giatti S, Ricigliano V A, Orzi F, Coccia EM, Salvetti M, Ristori G (2015) IFN-β and multiple sclerosis: from etiology to therapy and back. Cytokine Growth Factor Rev 26:221-228.

Gold R, Linington C, Lassmann H (2006) Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in multiple sclerosis. J Neuroimmunol 175:100-111.

Globovska M, Peplow PV (2020) Protective effects of pharmacological therapies in animal models of multiple sclerosis: a review of studies 2014–2019. Neural Regen Res 15(7):1220-1234. doi:10.4103/1673-5374.272572
Hedges K, Milward JM, Hentschel N, Infante-Duarte C, Akots O, Zipp F (2011) Neuroprotective effect of combination therapy of glatiramer acetate and epi-galactocerebrosides 3-galactide in neonatal treatment. PLoS One 6:e25456.

Hibbott N, Panu R, Wu TJ, Armstrong RC (2009) Cuprizone demyelination of the corpus callosum in mice correlates with early-onset social interaction and impaired bilateral sensorimotor coordination. ASN Neuro doi: 10.1042/AN20090032.

Hoodstra W, Zhang JH, Rühling S, Schmitz C, Kipp M (2018) Do pre-clinical multiple sclerosis models allow us to measure neurodegeneration and clinical progression? Expert Rev Neurother 18: 351-353.

Janssen A, Fiebiger S, Bros H, Hertwig L, Romero-Suarez A, Hamann I, Chanvillard C, Bellmann-Strobl J, Paul F, Milward JM, Infante-Duarte C (2015) Treatment of chronic experimental autoimmune encephalomyelitis with epi-galactocerebrosides 3-galactide and glatiramer acetate alters expression of heme-oxygenase 1 in CNS and SCS. J Neuroimmunol 283:52-57.

Jayaraman S, Soni A, Prabhakar BS, Holtermann M, Jayaraman S (2017) The epigenetic drug trichostatin A ameliorates experimental autoimmune encephalomyelitis. Nat Genet 49:1271-1276.

Proacocci C, De Rosa V, Piccin V, Formisano L, Matarese G (2015) Animal models of multiple sclerosis. Eur J Pharmacol 759:182-191.

Qiu X, Luo H, Liu X, Guo Q, Zheng K, Fan D, Shen J, Lu C, He X, Zhang G, Lu A (2018) Therapeutic potential of Potential Treatment on experimental autoimmune encephalomyelitis rat. J Immunol Res 2018:924718.

Rudick RA, Lee JC, Simon J, Ransohoff RM, Fisher E (2004) Defining interferon beta response status in multiple sclerosis patients. Ann Neurol 56:548-555.

Sanada F, Taniyama T, Muratsu J, Otsu R, Shimizu H, Rakugi H, Morishita R (2018) Source and severity of inflammation in aging. Front Cardiovasc Med 5:12.

Silva GA, Pradella F, Moraes A, Farias A, dos Santos LM, de Oliveira AL (2014) Impact of pregabalin treatment on synthetic plasticity and glial reactivity during the course of experimental autoimmune encephalomyelitis. Brain Behav 4:925-935.

Silva RBM, Greggio S, Venturin GT, da Costa J, Gomez MV, Campos MM (2018) Beneficial effects of the calcium channel blocker CTX 01512-2 in a mouse model of multiple sclerosis. Mol Neurobiol 55:9307-9327.

Skupuzela T, Lindner M, Kotsiara A, Garde N, Fokuhl J, Einsmeier F, Trebst C, Stangel M (2008) Cortical demyelination is prominent in the murine cuprizone model and is strain-dependent. Am J Pathol 172:1053-1061.

Sobel RA (2000) Genetic and epigenetic influence on EAE phenotypes induced with different encephalitogenic peptides. J Immunogenet 108:45-52.

Steenman AJ, Thompson JP, Li J (2012) Demyelination and remyelination in ana-tomically distinct regions of the corpus callosum following cuprizone intoxication. Neurosci Res 72:32-42.

Stromnes IM, Kuhlmann T, Matthews PM, Kilpatrick TJ (2017) Achievements and obstacles of remyelinating therapies in multiple sclerosis. Nat Rev Neurol 13:742-754.

Stromnes IM, Goverman JM (2006) Active induction of experimental allergic encephalomyelitis in adult mice. J Neurosci 26:10819-10829.

Stromnes IM, Goverman JM (2006b) Passive induction of experimental allergic encephalomyelitis. Nat Protoc 1:1952-1960.

Sihos KW, Fairless R, Williams SK, Heine K, Cavaliè A, Demir R (2014) N-methyl-D-aspartate receptor blockade is protective in experimental autoimmune optic neuritis. J Neuropath Exp Neurol 73:507-518.

Sui RX, Miao Q, Wang J, Wang Q, Song L, Yu JW, Cao L, Xiao W, Xiao BG, Ma CG (2019) Protective and therapeutic role of bilobalide in cuprizone-induced demyelination. Int Immunopharmacol 68:69-81.

Takeuchi C, Yamagata K, Takemiy Y (2013) Variation in experimental autoim-une encephalomyelitis scores in a mouse model of multiple sclerosis. World J Neurol 3:56-61.

Taylor LC, Gilmore W, Matsumasa GK (2009) SJL mice exposed to cuprizone intoxication reveal strain and gender pattern differences in demyelination. Brain Pathol 19:467-479.

Thompson KK, Nissen JC, Pretry A, Tsirka SE (2018) Tuftsin combines with re-myelinating therapy and improves outcomes in models of CNS demyelinating disease. Front Immunol 9:2784.

Toader LE, Roșu GC, Cătălin B, Pirică I, Gilca CE, Albu VC, Istrate-Oțteru AM, Mureșanu D, Pirică D (2018) Cerebrolysin increases motor recovery and decreases inflammation in a mouse model of autoimmune encephalitis. Rom J Morphol Embryol 59:755-762.

Trapp BD, Ransohoff RM, Fisher E, Rudick RA (1999) Neurodegeneration in multiple sclerosis: relationship to neurological disability. Neuroscientist 5:48-58.

Tsujoda I, Kuo LQ, Theil DJ, Fujimani RS (2000) Antibody association with a novel model for primary progressive multiple sclerosis: induction of relapsing-remitting and progressive forms of EAE in H2k mouse strains. Brain Pathol 10:402-418.

van der Star BJ, Vogel DY, Kipp M, Puentes F, Baker D, Amor S (2012) In vitro and in vivo models of multiple sclerosis. CNS Neurol Drug Target 11:570-588.

Vilillosada P (2016) Neuroprotective therapies for multiple sclerosis and other demyelinating diseases. Mult Scler Demyelinating Disord 1:1.

Wallin MT, Culppepper WJ, Campbell JD, Nelson LM, Langer-Gould A, Marrie RA, Cutter GR, Kaye WE, Wagner L, Tremlett H, Buka SL, Dildothorsakul P, Topol B, Chen LH, LaRocca NG (2019) The prevalence of MS in the United States: a population-based estimate using health claims data. Neurology 92:1029-1040.

Wang T, Xi NN, Chen Y, Shang XF, Hu Q, Chen JF, Zheng RY (2014) Chronic caffeine treatment prevents against experimental autoimmune encephalomyelitis in mice: therapeutic window and receptor subtype mechanism. Neuropharmacology 86:203-211.

Williams A (2015) Remyelination in multiple sclerosis: what do we know and where are we going? Neurodiffer Dis Manag 5:49-59.

Wootla B, Denic A, Warrington AE, Rodriguez M (2016) A monoclonal natural mouse antiserum that inhibits remyelination in vitro. J Neuroimmunol 293:1-9.

Zhang Y, Guo TB, Lu H (2013) Promoting remyelination for the treatment of multiple sclerosis: opportunities and challenges. Neurosci Bull 29:144-154.